| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $11,500,000 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Rachlin Evan Lockwood | director | 1 | $11.5M | 0 | $0 | $11.5M |
Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.
Over the last 12 months, insiders at Iambic Therapeutics Inc. have bought $11.5M and sold $0 worth of Iambic Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Iambic Therapeutics Inc. have bought $11.5M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rachlin Evan Lockwood (director) — $11.5M.
The last purchase of 718,750 shares for transaction amount of $11.5M was made by Rachlin Evan Lockwood (director) on 2026‑10‑16.
| 2026-10-16 | Rachlin Evan Lockwood | director | 718,750 5.1519% | $16.00 | $11.5M | -39.75% |
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |